Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19651518 | 0.80 | GAA (0.46) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL12595545 | 0.80 | GAA (0.46) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL22793171 | 0.70 | MAOA (0.52) | GAANPSR1MAOAMAOB | |
| SCHEMBL16306319 | 0.68 | GAA (0.56) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL11195016 | 0.67 | GAA (0.60) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL147262 | 0.67 | GAA (0.60) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL1368071 | 0.67 | GAA (1.00) | GAANPSR1MAOAMAOBOXTR | |
| SCHEMBL22792839 | 0.67 | CA12 (0.46) | GAANPSR1HTR5ACA12CA9 | |
| SCHEMBL22792943 | 0.67 | CA12 (0.46) | GAANPSR1HTR5ACA12CA9 | |
| Hydrochloric Acid SCHEMBL11181597 | 0.66 | GAA (0.58) | GAANPSR1MAOAMAOBOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | GAA 544/4885NPSR1 492/4885MAOA 15/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | GAA 544/4885NPSR1 492/4885MAOA 15/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | GAA 544/4885NPSR1 492/4885MAOA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.